1
M
aterials
D
esign
A
nalysis
R
eporting (MDAR)
Checklist for Authors
The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life scien
ces
(see Statement of Task:
doi:10.31222/osf.io/9sm4x.
). The MDAR checklist is a tool for authors, editors
,
and others seeking to a
dopt
the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document
for additional context for the MDAR framework.
2
For all that apply, please note where in the manuscript the required infor
mation is provided.
Materials
:
Newly created materials
indicate where provided: page no/section/legend)
n/a
The manuscript includes a dedicated "materials
availability statement" providing transparent
disclosure about availability of newly created
m
aterials including details on how materials
c
an be
accessed and describing any restrictions on access.
The material
access information is included in the
Acknowledgements section.
Antibodies
indicate where provided: page no/section/legend)
n/a
For commercial reagents, provide supplier name,
catalogue number and
RRID
, if available.
The information for antibodies, including supplier name,
catalogue number and RRID,
are
listed in Table S1
in
the
Supplementary Material
s
.
DNA and RNA sequences
indicate where provided: page no/section/legend)
n/a
Short novel
DNA or RNA
including primers, probes
:
Sequences
should be included or deposited in
a
public repository.
n/a
Cell materials
indicate where provided: page no/section/legend
n/a
Cell lines:
Provide species information, strain.
P
rovide accession number in repository
OR
supplier
name, catalog number, clone number,
OR
RRID
.
The information for cell
lines and associated materials
,
including supplier name, catalog number
, and
clone
number,
are lis
ted in Table S1 in the Supplementary
Materials
.
Primary cultures:
Provide species, strain, sex of
origin, genetic modification statu
s.
n/a
Experimental animals
indicate where provided: page no/section/legend)
n/a
Laboratory animals
or Model organisms
:
Provide
species, strain, sex, age, genetic modification status
.
Provide
a
ccession number in repository
OR
supplier
name, catalog number, clone number,
OR
RRID
.
n/a
Animal observed in or captured from the field:
Provide species, sex
,
and age where possible
.
n/a
Plants and microbes
indicate where provided: page no/section/legend)
n/a
Plants:
provide species and strain,
ecotype and
cultivar where relevant
,
unique accession number if
available, and source (including location for collected
wild specimens)
.
n/a
Microbes:
provide species and strain, unique
accession number if available, and source
.
The information for
microbes, including species, st
r
ain,
supplier name, and catalog number
are listed
in Table S1
in
the Supplementary Material
s
.
Human research participants
indicate where provided: page no/section/legend)
or
state if these demographics were not collected
n/a
If collected and within the bounds of privacy
constraints r
eport on age
,
sex and gender
or
ethnicity
for all study participants.
n/a
3
Design
:
Study protocol
indicate where
provided: page no/section/legend)
n/a
If study protocol has been pre
-
registered, provide
DOI.
For clinical trials, provide the trial registration
number
OR
cite DOI.
n/a
Laboratory protocol
indicate where provided: page
no/section/legend)
n/a
Provide DOI
OR
other citation details if detailed step
-
by
-
step protocols are available.
n/a
Experimental study design (statistics details)
For in vivo studies
:
State whether and how the
following have been done
indicate where provided: page no/section/legend. If
it could have been done, but was not, write not done
n/a
Sample size determination
n/a
Randomi
z
ation
n/a
Blinding
n/a
Inclusion/exclusion criteria
n/a
Sample definition and
in
-
laboratory replication
indicate where provided: page no/section/legend
n/a
State number of times the experiment was
replicated in laboratory
.
The
number of times an experiment was replicated
is
provided in the Materials and Methods section in the
Supplementary Materials.
Define whether data describe technical or biological
replicates
.
The usage of biological or
techn
ical
replicates
is
indicated in the Materials and Methods section in the
Supplementary Materials.
Ethics
indicate where provided: page no/section/legend
n/a
Studies involving human participants:
State details
of authority granting ethics approval (IRB or
equivalent committee(s), provide reference number
for approval.
n/a
Studies involving experimental animals:
State
details of authority granting ethics approval (IRB or
equivalent committee(s), provide reference number
for approval.
n/a
Studies involving specimen and field samples:
State
if relevant permits obtained, provide details of
authority approving study; if none were required,
explain why.
n/a
Dual Use Research of Concern (DURC)
indicate where provided: page no/section/legend
n/a
If
study is subject to dual use research of
concern
regulations
, state
the authority granting approval
and reference number for the regulatory approval.
n/a
4
Analysis
:
Attrition
indicate where provided: page no/section/legend
n/a
Describe whether exclusion criteria were
preestablished. Report if sample or data points were
omitted from analysis. If yes report if this was due to
attrition or intentional exclusion and provide
justification.
n/a
Statistics
indicate where
provided: page no/section/legend
n/a
Describe statistical tests used and justify choice of
tests.
n/a
Data
a
vailability
indicate where provided: page no/section/legend
n/a
For newly created and reused datasets, the
manuscript includes a data
availability statement
that provides details for access or notes restrictions
on access.
As indicated in the Acknowledgements section, t
he
coordinates and structure factors of
the
crystal
structures
have been deposited into the Protein Data
Bank
(PDB
)
.
PyMol and Chimera sessions
are
deposited on CaltechDATA
.
If newly created
data
sets
are publicly available,
provide accession number in repository
OR
DOI
OR
URL and licensing details where available.
Accession codes and DOIs are provided in
the
Acknowledgements section.
If
reused data is
publicly available provide accession
number in repository
OR
DOI
OR
URL,
OR
citation.
n/a
Code
a
vailability
indicate where provided: page no/section/legend
n/a
For all newly generated custom computer
code/software/mathematical algorithm or re
-
used
code essential for replicating the main findings of
the study, the manuscript includes a data availability
statement that provides details for access or notes
restrictions.
As indicated in the Acknowledgement
s section, the
docking
data and
workflow code
are
deposited on
CaltechDATA
.
If newly generated code is publicly available, provide
accession number in
repository,
OR
DOI
OR
URL and
licensing details where
available. State any
restrictions on code availability or accessibility
.
DOI is provided in Acknowledgements section.
If reused code is
publicly available provide accession
number in repository
OR
DOI
OR
URL,
OR
citation.
n/a
5
Reporting
MDAR framework recommends adoption of discipline
-
specific guidelines, established
and endorsed through community
initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.
Adherence to community standards
indicate where provided: page no/section/legend
n/a
State if
relevant guidelines (e.g., ICMJE, MIBBI,
ARRIVE) have been followed, and whether a checklist
(e.g., CONSORT, PRISMA, ARRIVE) is provided with
the manuscript.
n/a